[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT01832350 : Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease|
|Ages||Min: 55 Years Max: 90 Years|
- Male/female 55 to 90 years, inclusive.
- Meets National Institute of Neurological and Communicative Disorders and
Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable
- Modified Hachinski Ischemia Scale score of ?4.
- Folstein Mini Mental State Exam score 16-26 at Visit 1.
- Geriatric Depression Scale score ?6. For patient with history of depression, he/she
have been on steady dose of anti-depressant for at least 3 months.
- Clinical history and relevant symptoms of Pseudobulbar Affect.
- Center for Neurologic Study-Lability Scale score at baseline ?13.
- Stable hematologic, hepatic, and renal function, with no clinically significant
symptoms, and with clinical laboratory results (CBC, clinical chemistry, and
urinalysis) up to 1-fold higher than upper limit of normal range.
- Resting respiratory rate 12-20/minute.
- MRI or CT scan within past 12 months; no findings inconsistent with diagnosis of AD.
- ECG (within 4 weeks prior to entry)with no evidence of clinically significant
- Concurrent treatment with an acetylcholinesterase inhibitor or memantine allowed;
must be on stable dose at least 2 months before screening. Dosing must remain stable
throughout the study.
- Use of SSRI's allowed. Must have used for 3 months prior to study entry; dose must
remain unchanged during course of study.
- No current symptoms of depressive disorder.
- Score of 19 or lower in the Beck Depression Inventory.
- Agrees to use no prohibited medications during study.
- Has current serious or unstable illnesses that, in investigator's opinion, could
interfere with analysis of safety and efficacy data; has life expectancy <2 years.
- No reliable caregiver in frequent contact with patient (at least 10 hours/week.
- Current or prior history of major psychiatric disturbance.
- Have been in other clinical study within 30 days of entry.
- Score of 20 or higher in Beck Depression Inventory.
- Multiple episodes of head trauma, history within last year of serious infectious
disease affecting the brain, head trauma resulting in protracted loss of
consciousness, or myasthenia gravis.
- Within the last 5 years, history of a primary or recurrent malignant disease.
- Known sensitivity to quinidine or dextromethorphan.
- History of human immunodeficiency virus, multiple or severe drug allergies, or severe
post-treatment hypersensitivity reactions.
- History of chronic alcohol or drug abuse/dependence within the past 5 years.
- Judged by investigator to be at serious risk for suicide.
- Has a recent or current lab result indicating clinically significant lab abnormality.
- At Visit 1 has ALT/SGPT values ?2 times upper limit of normal (ULN); AST/SGOT values
?3 times the ULN; total bilirubin values ?2 times the ULN.
- Resting diurnal oxygen saturation <95%.
- Received dextromethorphan and quinidine within previous 6 months.
- Hypotension (systolic BP <100 mm Hg); postural syncope; unexplained syncope.
- Used medications that affect the CNS (except for AD) for less than 4 weeks.
- On disallowed concomitant medications.
- Experiencing acute exacerbation of underlying neurological disorder within previous 2
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01832350
| Link to official Clinicaltrials.gov listing